Agenus Inc. (NASDAQ:AGEN) Short Interest Up 56.5% in December

Agenus Inc. (NASDAQ:AGEN) saw a large growth in short interest in December. As of December 15th, there was short interest totaling 2,774,043 shares, a growth of 56.5% from the November 30th total of 1,772,528 shares. Based on an average daily trading volume, of 536,401 shares, the days-to-cover ratio is currently 5.2 days. Approximately 8.6% of the company’s shares are sold short. Approximately 8.6% of the company’s shares are sold short. Based on an average daily trading volume, of 536,401 shares, the days-to-cover ratio is currently 5.2 days.

Agenus Stock Down 2.2%

Shares of AGEN stock opened at $3.12 on Wednesday. The firm has a market cap of $106.11 million, a price-to-earnings ratio of -1.46 and a beta of 1.51. Agenus has a 52-week low of $1.38 and a 52-week high of $7.34. The company’s 50 day moving average is $3.96 and its 200 day moving average is $4.53.

Agenus (NASDAQ:AGEN) last announced its earnings results on Monday, November 10th. The biotechnology company reported $1.94 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.63 by ($0.69). The business had revenue of $30.24 million during the quarter, compared to analyst estimates of $80.39 million. Analysts anticipate that Agenus will post -12.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Agenus

A number of large investors have recently added to or reduced their stakes in AGEN. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Agenus during the second quarter valued at about $50,000. Jump Financial LLC purchased a new stake in Agenus during the second quarter valued at approximately $55,000. Traynor Capital Management Inc. purchased a new stake in Agenus during the third quarter valued at approximately $50,000. Squarepoint Ops LLC acquired a new stake in Agenus in the third quarter valued at approximately $54,000. Finally, Savant Capital LLC acquired a new stake in shares of Agenus in the 2nd quarter worth $73,000. 61.46% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AGEN. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Agenus in a research report on Monday. HC Wainwright reissued a “buy” rating on shares of Agenus in a research note on Monday, October 20th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Agenus has an average rating of “Hold” and a consensus price target of $14.50.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.